SGLT2 inhibitors should be considered foundational therapy in all patients with heart failure, irrespective of LVEF or care setting in order to help prevent hospitalization, morbidity and mortality and to extend meaningful survival and improve health-related quality of life. Here, SLC5A2 is linked to heart failure.